Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Mult Scler. 2013 Aug;19(9):1236-7. doi: 10.1177/1352458512468498. Epub 2012 Nov 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Drug Substitution*
  • Female
  • Fingolimod Hydrochloride
  • Humans
  • Immunologic Factors / administration & dosage*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab
  • Propylene Glycols / administration & dosage*
  • Sphingosine / administration & dosage
  • Sphingosine / analogs & derivatives*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Natalizumab
  • Propylene Glycols
  • Fingolimod Hydrochloride
  • Sphingosine